Recognized for Developing and Commercializing Korea's First Minimally Invasive Glaucoma Implant, "A-stream"

Provided by Microtote

Provided by Microtote

View original image

Microtote, a company specializing in ophthalmology, announced on the 28th that it received the Minister of Trade, Industry and Energy Award in the Bio Innovation Growth category at the "2025 Bio Industry Day" event, hosted by the Ministry of Trade, Industry and Energy and organized by the Korea Bio Association and others. The award recognizes the company's development of "A-stream," Korea's first minimally invasive glaucoma surgery implant, which has demonstrated the competitiveness of domestic technology and contributed to the localization of medical device technology.


A-stream is a minimally invasive glaucoma implant commercialized by Microtote, based on clinical data from the glaucoma research team at Samsung Medical Center. The device features a sophisticated design, including a 6mm-long medical-grade silicone tube, an inner diameter of 100 micrometers, and a ripcord that allows for stepwise intraocular pressure control.


After receiving approval from the Ministry of Food and Drug Safety in September 2023, the product was included in the National Health Insurance reimbursement scheme in February 2024 and quickly spread to medical institutions across the country. Within just over a year of its launch, the device was coded at more than 80 medical institutions, with cumulative procedures exceeding 2,000 cases. This is seen as a case where a domestic product has rapidly established a solid position in the glaucoma implant market, which had been dominated by foreign products.


Clinical outcomes have also been demonstrated. In a multi-center retrospective study, A-stream reduced average intraocular pressure by approximately 56% six months after surgery and decreased the number of glaucoma medications used from 3.3 to 0.3. A total of 93.9% of patients achieved target intraocular pressure without medication, demonstrating excellent therapeutic effects. In addition, with full reimbursement for treatment material costs, patients' out-of-pocket expenses remained around 200,000 won, significantly reducing the financial burden compared to major foreign implants and contributing to the product's widespread adoption.



Microtote manufactures A-stream at a GMP-certified production facility and is preparing for FDA 510(k) approval to enter the global market. The company stated, "This award is a meaningful achievement that officially recognizes the competitiveness of Korean medical devices," and added, "We will establish a new standard based on domestic technology in the glaucoma surgery market, which has long been heavily dependent on foreign products."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing